Target Name: MCRIP2
NCBI ID: G84331
Review Report on MCRIP2 Target / Biomarker Content of Review Report on MCRIP2 Target / Biomarker
MCRIP2
Other Name(s): FAM195A | MAPK regulated corepressor interacting protein 2 (isoform 1) | MCRI2_HUMAN | MCRIP2 variant 1 | c349E10.1 | C16orf14 | family with sequence similarity 195, member A | MAPK regulated corepressor interacting protein 2, transcript variant 1 | protein FAM195A | MAPK regulated corepressor interacting protein 2 | MAPK regulated co-repressor interacting protein 2

MCRIP2: A Potential Drug Target for Cancer and Regenerative Medicine

MCRIP2 (FAM195A) is a protein that is expressed in various tissues of the body, including the brain, heart, and lungs. It is a member of the superfamily of FAM (fucosin) proteins, which are known for their role in cell signaling and membrane structure. MCRIP2 has been shown to be involved in a variety of physiological processes in the body, including cell adhesion, migration, and invasion.

One of the unique features of MCRIP2 is its ability to interact with the protein FAM195A. FAM195A is a member of the FAM195 family, which includes a variety of proteins that are involved in cellular signaling. MCRIP2 has been shown to physically interact with FAM195A, leading to the formation of a complex that is involved in the regulation of cellular processes.

This interaction between MCRIP2 and FAM195A is of particular interest because it suggests that MCRIP2 may be a drug target or biomarker. By targeting MCRIP2 with small molecules or other compounds, researchers may be able to interfere with the regulation of cellular processes that are important for cancer growth, treatment, and survival.

One of the potential benefits of targeting MCRIP2 is its involvement in cancer progression. MCRIP2 has been shown to be involved in the regulation of cell migration and invasion, which are important processes that contribute to cancer cell progression. By inhibiting MCRIP2 function, researchers may be able to slow down or stop the growth and spread of cancer cells.

Another potential application of MCRIP2 as a drug target is its role in the regulation of cellular signaling pathways. MCRIP2 has been shown to be involved in a variety of signaling pathways, including the regulation of cell adhesion, migration, and invasion. By targeting MCRIP2 with small molecules or other compounds, researchers may be able to disrupt these signaling pathways and inhibit the growth and spread of cancer cells.

MCRIP2 has also been shown to be involved in the regulation of inflammation and fibrosis. These processes can contribute to the development and progression of a variety of diseases, including cancer. By targeting MCRIP2 with small molecules or other compounds, researchers may be able to inhibit the production of pro-inflammatory cytokines and improve the regulation of fibrosis.

Targeting MCRIP2 may also have potential applications in regenerative medicine. MCRIP2 has been shown to be involved in the regulation of cell proliferation and differentiation, which are important processes for the development and repair of tissues. By targeting MCRIP2 with small molecules or other compounds, researchers may be able to stimulate the growth and differentiation of stem cells and improve the development of tissues for transplantation.

In conclusion, MCRIP2 is a protein that is involved in a variety of physiological processes in the body. Its interaction with the protein FAM195A suggests that it may be a drug target or biomarker. Targeting MCRIP2 with small molecules or other compounds may be a promising strategy for the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of MCRIP2 in cellular signaling and to determine its potential as a drug target or biomarker.

Protein Name: MAPK Regulated Corepressor Interacting Protein 2

The "MCRIP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MCRIP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8 | MED9 | MEDAG | Mediator Complex | Mediator of RNA Polymerase II Transcription | MEF2A | MEF2B | MEF2C | MEF2C-AS1 | MEF2C-AS2 | MEF2D | MEFV | MEG3 | MEG8 | MEG9 | MEGF10 | MEGF11 | MEGF6 | MEGF8 | MEGF9 | MEI1 | MEI4 | MEIG1 | MEIKIN | MEIOB | MEIOC | MEIOSIN | MEIS1 | MEIS1-AS2 | MEIS1-AS3 | MEIS2 | MEIS3 | MEIS3P1